Open Menu Close Menu Open Search Close Search

Non-Invasive Neurostimulation in AD/ADRD (R01 Clinical Trial Optional)

The goal of this Funding Opportunity Announcement (FOA) is to encourage applications for studies using non-invasive neurostimulation/neuromodulation in the treatment of Alzheimer’s disease (AD) or Alzheimer’s disease-related dementias (ADRD). The goal of this FOA is to establish initial efficacy of neurostimulation/neuromodulation in the treatment of AD/ADRD or to refine these interventions for AD/ADRD patients. Multimodal or combination interventions are allowed, provided the focus and innovative component is neurostimulation. Applications that seek to develop devices, tools, or invasive techniques are outside the scope of this FOA.

Application Due Date(s): Standard dates apply (new R01 Feb.5, Jun. 5, Oct. 5).